Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Light, R. W.
Right arrow Articles by Webster, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Light, R. W.
Right arrow Articles by Webster, J. S.
(Chest. 1996;109:975-981.)
© 1996 American College of Chest Physicians

Effect of 30 mg of Morphine Alone or With Promethazine or Prochlorperazine on the Exercise Capacity of Patients With COPD

Richard W. Light MD, FCCP1; David W. Stansbury RRT1; and Jeffrey S. Webster PhD1

1 From the Department of Medicine, Veterans Affairs Medical Center, Long Beach, Calif, and the University of California Irvine

Objective: We have shown that the administration of 0.8 mg/kg of morphine (M) to patients with COPD resulted in a 20% increase in the maximum oxygen consumption (VO2max), but was associated with significant drowsiness and euphoria. The objective of the present study was to ascertain whether lower doses of M alone or in combination with prochlorperazine (PC) or promethazine (P) could elicit significant increases in exercise tolerance.

Design: The exercise capacity, psychological status, and reaction times were assessed before and 60 min after the patients received placebo (PLAC), 30 mg M orally, 30 mg M plus 10 mg PC (M-PC), or 30 mg M plus 25 mg P (M-P) in a randomized double-blind crossover study. In a secondary study, nine patients were tested on three separate days before and after receiving PLAC, 25 mg P, or 30 mg M plus 25 mg P.

Patients: Seven COPD patients (FEV1=0.99±0.30 L, VO2max=990±315 mL/min) who were ventilatory-limited.

Setting: Veterans Affairs medical center.

Results: After the patients ingested M-P, the increase in the VO2max (129.0±104 mL/min), the workload (10.0±6.5 W) and the maximum minute ventilation (4.0±3.9 L/min) were significantly greater (p<0.05) than after PLAC ingestion (minus4.8±79 mL/min, 1.4±6.9 W, and minus1.6±2.4 L/min, respectively). Changes after the ingestion of M, P, or M-PC were intermediate. The M-PC combination adversely affected the patient's reported mental status (Bond visual analog scale) more than the M-P or M regimens. No regimen significantly affected the reaction time.

Conclusions: We conclude that the administration of 30 mg of M plus 25 mg of P significantly improves the exercise tolerance of patients with COPD, without significantly impairing the mental capabilities of the subjects. The utility of this regimen over longer time periods needs to be evaluated.

Key Words: emphysema • exercise • obstructive lung disease • opiates • promethazine

Submitted on June 20, 1995
Accepted on October 12, 2007




This article has been cited by other articles:


Home page
ThoraxHome page
A-L Jennings, A N Davies, J P T Higgins, J S R Gibbs, and K E Broadley
A systematic review of the use of opioids in the management of dyspnoea
Thorax, November 1, 2002; 57(11): 939 - 944.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American College of Chest Physicians.